tbuckley/cabot-search huggingface dataset:
68 Ga-PSMA PET/CT for preoperative lymph nosde staging of high-risk prostate cancer.
Authors: Axel Heidenreich, Maximilian Schmautz, David A. Pfister, Florian Hartmann
Journal: Journal of Clinical Oncology (2022)

38 Background: The present study evaluates the potential role of 68 Ga-PSMA PET/CT to detect pelvic lymph node metastases in newly diagnosed, treatment-naïve high risk prostate cancer (PCa) patients prior to radical prostatectomy and extended pelvic lymphadenectomy. Methods: A total of 165 men with newly diagnosed high risk PCa (ISUP grade 4/5, PSA &gt; 20 ng/ml or ≥cT3a) were included in this retrospective analysis. All men had undergone a transperineal MR fusion biopsy and all men underwent RPE with epLND. Patients with neoadjuvant ADT, TRUS guided biopsies, previous radiation or surgeries in the small pelvis were excluded. Imaging findings and pathohistological findings were correlated and sensitivity, specificity, positive and negative predictive values were calculated. The correlation of clinical and biopsy characteristics with PSMA PET/CT. Results: The median PSA was 24.5 (6.7-185) ng/ml, the median number of dissected lymph nodes was 21-5 (14-45). A total of 68/165 (41,2%) patients had lymph node metastases (LNM) of which 43 (63.2%) were positive on PSMA-PET/CT whereas 25 (36.8%) LNM were negative on PSMA PET/CT. 97/165 (58.8%) pts had pN0 disease of whom 93 (95.9%) and 3 (4.1%) demonstrated negative and positive PSMA PE/CT findings, resp. n = 47 had positive PSMA PET/CT and 40 (85.1%) demonstrated LNM, 7 (14.9%) had pN0 disease. N = 118 had negative PSMA PET/CT of which 93 (78.8%) and 25 (21.2%) were true and false negative, resp. Sensitivity was 63.2%, specificity was 97.0%, and positive and negative predictive values were 93.5% and 78,8%, respectively. 3564 lymph nodes were resected, 149 (4.2%) had LNM. 88/149 (59.1%) were detected on PSMA PET/CT and 61 (40.9%) were undetected. On a per lymph node base, sensitivity and specificity were 40.4% and 94.5%, resp; positive and negative predictive values were 59.1% and 97.3%. Conclusions: PSMA-PET/CT has a high reliability to identify patients with high risk PCA and LNM. If a positive lesion is detected, epLND is mandatory due to high frequency of undetected small LNM. PSMA-PET/CT, is superior to standard imaging and it might replace CT/MRI of the small pelvis.
"Mushroom" Poisoning
Authors: C. T. Parsons
Journal: BMJ (1947)

welcomed by those able to afford it, but with present living conditions I do not think much of it has been peeled or washed before consumption.Many of these fruits were picked and packed in countries where the British population would not dream of eating them without previous washing in a weak solution of some oxidizing agent.It-is known that the virus of poliomyelitis is easily destroyed by oxidizing agents (Jos.Stokes, jun., in 'Textbook of Pediatrics (edit.W. E. Nelson), Philadelphia, 1946, p. 479).I feel that a more vigorous campaign among the public, in- cluding those serving meals and uncooked food, for more care in handling and in washing up all utensils is called for urgently.-I am, etc., Winchester.MYRTLE M. HUTCHINS.SIR,-In an article on acute poliomyelitis by Dr. W. H. Kelleher (Aug.23, p. 291) the opinion of American observers is quoted that "perhaps 98% of poliomyelitis is a mild, wide- spread, highly communicable disease, mainly of young children, leaving no residual paralysis . .." Tis opinion is valid for the present outbreak of the disease in this country, and the presence of the specific virus is not the only factor necessary for producing the disease in a clinically recognizable form.It is very important to discover what it is that has been added to the virus in 2% of people to produce serious disease of the nervous system.To solve this problem a study of clinical and environmental factors must be made of the patients and their, known contacts, using the knowledge of the virus as an indi- cator of the people at risk.Recent outbreaks of smallpox4 enteric fever, and of other acute diseases, as well as chronic infections such as tuberculosis and chronic pyogenic disease, show how large is the unknown factor in the equation: specific organism plus x equals disease.A revival of epidemiology is needed, with knowledge of bacteria and viruses as an aid instead of the insufficient substitute which it has been for many years.Clinicians must take a bold part in this revival.-I am, etc.,
Entropy as a Measure of Myocardial Tissue Heterogeneity in Patients With Ventricular Arrhythmias
Authors: Panagiotis Antiochos, Yin Ge, Rob J. van der Geest, Chaitanya Madamanchi, Iqra Qamar, Ayako Seno, Michael Jerosch-Herold, Usha B. Tedrow, William G. Stevenson, Raymond Y. Kwong
Journal: JACC. Cardiovascular imaging (2022)
Borderline substances.
Authors: R J Woodward, R Baxter
Journal: BMJ (1978)

mg four times a day, and then to 160 mg four times a day.His ECG initially showed widespread T-wave inversion, but this abnor- mality was most marked two days later, with gross T-wave inversion in most leads (figure).Serial enzyme studies failed to confirm myocardial damage.... ..~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~...... ~~Ṽ4 ~~~~~V ECG of patient with subarachnoid haemorrhage showing T-wave inversion.Thus this patient was already taking a beta-blocker, in a dose comparable to 240 mg propranolol, but despite a further increase in dosage and apparently clinically adequate beta- blockade (resting pulse rate about 60 beats/ min) he proceeded to develop grossly abnormal ECG appearances, of a severity which we have not previously observed in association with subarachnoid haemorrhage.
Mortality After Late Breast Cancer Recurrence in Denmark
Authors: Rikke Nørgaard Pedersen, Lene Mellemkjær, Bent Ejlertsen, Mette Nørgaard, Deirdre P. Cronin-Fenton
Journal: Journal of Clinical Oncology (2022)

PURPOSE Late breast cancer (BC) recurrence (ie, ≥ 10 years after primary diagnosis) may have a more favorable prognosis than earlier recurrence. We investigated the risk of BC death after late recurrence, identified prognostic factors, and compared survival after early and late recurrence. METHODS Using the Danish Breast Cancer Group and other nationwide databases, we identified women with early or late BC recurrence during 2004-2018, who were alive 6 months after recurrence. We followed them until BC death, death from other causes, emigration, 10 years, or December 31, 2018, whichever came first. We calculated mortality rates (MRs) per 1,000 person-years (PY) and cumulative BC mortality, for early versus late recurrence, and by characteristics of the primary tumor and the late recurrence. Using Cox regression, we calculated adjusted hazard ratios (HRs) for BC death, accounting for death from other causes as competing risks. RESULTS Among 2,004 patients with late recurrence, 721 died of BC with a median survival time of 10 years (MR = 84.8 per 1,000 PY; 10-year cumulative mortality = 50%). Among 1,528 patients with early recurrence, 1,092 BC deaths occurred with a median survival time of 4 years (MR = 173.9 per 1,000 PY; 10-year cumulative mortality = 72%). We observed a lower hazard of BC-specific death among patients who developed late compared with early recurrence (hazard ratio = 0.72; 95% CI, 0.62 to 0.85). Advanced stage at primary diagnosis, distant metastases, adjuvant treatment for locoregional recurrence, and systemic treatment for distant recurrence were associated with increased mortality after late recurrence. Breast-conserving surgery at primary diagnosis, locoregional recurrence, and surgery for recurrence were associated with lower mortality after late recurrence. CONCLUSION Patients with late recurrence had more favorable prognosis than patients with early recurrence. The localization of recurrent disease was the main prognostic factor for BC death.
10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2019</i>
Journal: Diabetes Care (2018)

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).
Authors: Daniel Joseph Khalaf, Liheng Chen, Katherine Sunderland, Joanna Vergidis, Krista Noonan, Daygen L. Finch, Muhammad Zulfiqar, Kim N. Chi
Journal: Journal of Clinical Oncology (2022)

60 Background: Combined ADT and ARPI is associated with improved overall survival (OS) compared with ADT alone in patients with mCSPC. The activity of subsequent therapies for mCRPC is not well characterized. Methods: We conducted a retrospective analysis of patients enrolled on a biobank at 6 cancer centres in British Columbia, Canada. Patients who received abiraterone or apalutamide for mCSPC were included. Data including baseline clinical prognostic factors and clinical outcomes (per Prostate Cancer Working Group III) were collected from patient records. Survival was analyzed by Kaplan-Meier method and Log Rank test and prognostic variables were determined using Cox regression. Results: 168 patients were identified of which 126 (75%) received abiraterone, 38 (23%) received apalutamide, and 4 (2%) received one ARPI and switched to the other for toxicity. Median age was 69 years and Gleason score ≥ 8 in 61%. Site of metastasis (mets) at mCSPC was lymph node (n=91), bone (n=141), and liver (n=6). As of August 28 2021, a total of 46 patients progressed to mCRPC, of which 38 received subsequent systemic therapy. First-line mCRPC treatments were docetaxel (n=12), Radium-223 (10), enzalutamide (6), platinum chemotherapy (3), and others (7) including immune checkpoint inhibitors (1) and Lutetium 177 -PSMA-617 (1) and other investigational agents (5). Outcomes are shown in the table. On univariate Cox analysis, clinical factors at time of mCRPC associated with worse OS were: LDH above upper limit of normal (HR 5.0, 95% CI 1.7-14.5), hemoglobin below lower limit of normal (5.2, 1.1-23.8), presence of ≥ 20 bone mets (3.7, 1.4-9.8), and increasing PSA (1.002, 1.001-1.003). Conclusions: PSA decline rates and survival are modest for patients who have progressed following upfront abiraterone or apalutamide plus ADT for mCSPC. Further follow-up is required to accurately determine outcomes with current mCRPC standard therapies following up-front ADT+ ARPI. Recently approved treatment options such as Lutetium 177 -PSMA-617 and PARP inhibitors for DNA damage repair deficient tumors may help to improve outcomes for these patients.[Table: see text]
Constructions of ROS-responsive titanium-hydroxyapatite implant for mesenchymal stem cell recruitment in peri-implant space and bone formation in osteoporosis microenvironment
Authors: Maohua Chen, Yuting Sun, Yanhua Hou, Zhong Luo, Menghuan Li, Yujia Wei, Maowen Chen, Lu Tan, Kaiyong Cai, Yan Hu
Journal: Bioactive Materials (2022)
Transurethral resection.
Authors: M Minuck
Journal: BMJ (1970)

sudden pain in the calf to death from mas- sive pulmonary embolism.Apprehension still exists as continuing investigations indicate that there are grave discrepancies in the recommended methods of laundering and sterilizing in the hospital service.The non-clinical approach is paramount.Hospital flora are now accepted, apparently calmly (8 August, p. 305).Just how far have we gone backwards in 22 years?Do we need another Lister?-Iam, etc.,
Correction
Journal: BMJ (1923)

MZDICAL JOUUNAShas not yet been ascertained.It was flrst noted in 1897 in New Guinea, but it has been observed also in Siam, Java, Madagascar, in both French and British Guinea, and in Algeria.Drs.Castellani and Tejera describe a skin disease of which we have not previously heard.It occurs in venezuela, where it is called "I cute " and is said to be fairly dommon.Bright yellow patches with little or no desquama- tlion appear sometimes in childhood, and very slowly spread.Xt is thougit to be Identical with an infection described by gastellani in Ceylon under the name of tinea flava.Spores rere observed in scrapings from the yellow patches, but no iungus growth could be obtained from them.
CORN IN THE WAR TIME DIETARY
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
American Review of Respiratory Diseases, New York
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Archives of Ophthalmology, Chicago
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Copanlisib Produces Prolonged Responses in Lymphoma
Journal: Cancer Discovery (2017)

Abstract A phase II trial of the pan-class I PI3K inhibitor copanlisib demonstrated that it induces objective responses in 59% of patients with relapsed or refractory indolent lymphoma. The responses lasted a median of 22.6 months. Although the drugs weren't compared head to head, researchers suspect that the side effects of copanlisib may be less severe than those of idelalisib, another PI3K inhibitor.
Annals Graphic Medicine - How the Virus Stole Anatomy
Authors: Stefan Tigges, Patricia J. Ward
Journal: Annals of Internal Medicine (2020)

Web Exclusives20 October 2020Annals Graphic Medicine - How the Virus Stole AnatomyFREEStefan Tigges, MD and Patricia J. Ward, PhDStefan Tigges, MDEmory University School of Medicine, Atlanta, Georgia (S.T.)Search for more papers by this author and Patricia J. Ward, PhDEmory University, Atlanta, Georgia (P.J.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G20-0048 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Emory University School of Medicine, Atlanta, Georgia (S.T.)Emory University, Atlanta, Georgia (P.J.W.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G20-0048.Author/Illustrator Information: Stefan Tigges, MD (e-mail, [email protected]edu); Patricia J. Ward, PhD (e-mail, jill.[email protected]edu).This article was published at Annals.org on 2 July 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHow to Safely Reopen Colleges and Universities During COVID-19: Experiences From Taiwan Shao-Yi Cheng , C. Jason Wang , April Chiung-Tao Shen , and Shan-Chwen Chang Metrics 20 October 2020Volume 173, Issue 8Page: W135-W142 ePublished: 2 July 2020 Issue Published: 20 October 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC).
Authors: Andrew Warren Hahn, Xuemei Wang, Eleni Efstathiou, Hyunsoo Hwang, Amado J. Zurita, Nicholas Spetsieris, Myrto A Boukovala, Jennifer Wang, John C. Araujo, Patrick Glen Pilie, Bilal A. Siddiqui, Sumit Kumar Subudhi, Paul Gettys Corn, Ana Aparicio, Shi-Ming Tu, Christopher Logothetis
Journal: Journal of Clinical Oncology (2022)

135 Background: In pre-operative studies, a short duration of AA + LHRHa produced marked cytoreduction in a subset of men with high-risk prostate cancer (PCa). However, in M0HNPC, androgen signaling inhibition (ASI) is reserved for men with short PSA doubling time. We reasoned that the subset of men who experience cytoreduction with pre-operative AA + LHRHa would also benefit from a short duration of AA + LHRHa at PSA recurrence. This report is a one-year follow-up of our second analysis (ASCO Annual Meeting 2018; PMID 34536949). Methods: FINITE is a phase II trial that randomized (1:1) to two treatment groups, 8 months of LHRHa alone or LHRHa plus AA 1000 mg and prednisone 5 mg daily (NCT01786265). Eligible patients had a rising PSA after definitive therapy and no prior systemic therapy. At disease progression, men were eligible for crossover to 8 months of the alternative therapy. The primary endpoint was PSA-free survival at 12 months (≤ 0.1 ng/dL). Time to PSA progression was calculated from date of initial treatment to date of PSA progression, defined as first occurrence of a rising PSA, if PSA remained detectable after treatment, or when the PSA ≥ 1 ng/dL, if it was undetectable after treatment and confirmed 4 weeks thereafter. The probabilities of PSA progression were defined using the Kaplan-Meier method. Results: 199 men were randomized, and 197 received initial treatment (LHRHa = 99, LHRHa + AA = 98). Median age at enrollment was 65 years, median PSA was 0.95 ng/dL (range 0.1 – 33.3), and median testosterone was 342.5 ng/dL (10-986). At data cut-off (October 1, 2021), men who received LHRHa + AA were more likely to be PSA-free 12 months after completing treatment (34% vs. 19%, p = 0.02). 168 men (85%) had experienced PSA progression, and median time to PSA progression was 24.3 months for entire cohort. Receipt of LHRHa + AA was associated with longer time to PSA progression than LHRHa alone (27.2 vs. 19.9 months, p = 0.003). Conclusions: Our findings support that finite treatment with AA + LHRHa produces more durable disease-free survival than LHRHa. The finite duration of AA + LHRHa is a toxicity-sparing approach that may allow for a transition from a treatment to curative paradigm for a subset of men with M0HNPC. Further analyses will aim to link the subset of men who benefit from finite AA + LHRHa between localized high-risk PCa and M0HNPC. Clinical trial information: NCT01786265.